Traxoprodil: The future of Depression Treatment
What an early depression trial revealed about a selective NMDA-receptor approach, why traxoprodil's development stopped, and how its research legacy continues.

In this article
Traxoprodil helped explore an important possibility: could targeting a particular glutamate receptor produce an antidepressant effect when an existing medicine had not helped? An early human study offered an encouraging signal. The compound's development was later halted over cardiac-safety concerns, but the search for treatments acting on this target has continued.13
What is traxoprodil?
Traxoprodil, also called CP-101,606, is an investigational compound developed by Pfizer. It belongs to a family of experimental medicines that selectively inhibit a particular subtype of NMDA receptor.2
Later research describes its development as halted over QTc prolongation, a cardiac electrical-timing concern. It should be discussed as a research compound, not an upcoming prescription option.3
How its mechanism differs from many antidepressants
Glutamate is a chemical messenger used by nerve cells. NMDA receptors are one family of glutamate-responsive ion channels: proteins that help regulate electrical signaling across the cell membrane. These receptors are assembled from different subunits, and traxoprodil selectively inhibits receptors containing GluN2B, formerly called NR2B.25
It acts as a negative allosteric modulator. In plain language, it binds at a regulatory site and turns down receptor activity, rather than competing directly at glutamate's binding site. Structural research on this drug family helps explain how different compounds can influence the same receptor through particular molecular interactions.2
This is a different starting point from serotonin-reuptake inhibition. It also differs from ketamine's broader NMDA-channel-blocking action. The hope is to find a useful balance between antidepressant effects and tolerability; targeting a narrower receptor subtype does not automatically establish that balance in patients.5
What the early depression trial found
In a 2008 double-blind trial, 30 people who had not improved during six weeks of paroxetine treatment received one infusion of traxoprodil or placebo while continuing paroxetine. At day five, traxoprodil produced an 8.6-point greater reduction on the study's main depression-rating scale.1
Response on a second depression scale was 60% with traxoprodil versus 20% with placebo. Response means substantial symptom improvement, not necessarily remission or a lasting cure. The small proof-of-concept study used an exploratory statistical threshold of P < .10 and an 80% confidence interval, so the findings were a signal for further testing rather than a definitive treatment result.1
Why safety changed the development story
QTc-related development problems are more consequential than a generic list of possible headaches or nausea. Receptor selectivity is not a safety guarantee.3
These are questions for monitored research, not a do-it-yourself experiment. There is no established patient dosing plan to offer here; products sold as research chemicals are not substitutes for prescribed care.3
What about sleep, anxiety, or brain injury?
The sleep-related wording in this page's URL should not be read as evidence that traxoprodil treats insomnia. In a rodent study comparing it with S-ketamine, traxoprodil did not alter sleep-wake architecture at the tested doses. That is a finding about animal sleep patterns, not a demonstration of better sleep in people.5
The earlier article also discussed neuroprotection. A randomized trial in 404 people with severe traumatic brain injury found numerical differences favoring traxoprodil, but did not establish definitive efficacy. The six-month favorable-outcome comparison was not statistically significant. Encouraging laboratory findings and clinical benefit are separate steps.4
Likewise, the depression infusion trial did not establish treatment of an anxiety disorder. It is more accurate to keep the depression findings specific than to extend them to every condition involving glutamate.1
The hopeful part: the research did not end there
Onfasprodil (MIJ821), a different GluN2B-selective modulator, was studied in a phase 2 trial reported in 2025. Among 70 treated participants, pooled onfasprodil groups showed greater depression-score improvements than placebo at 24 hours.3
That is not a revival or approval of traxoprodil. It is an encouraging continuation of research on the target, with the goal of finding a dependable balance of benefit and safety.3
What this means if you need help now
You do not have to wait for an experimental compound to discuss another treatment plan. Depending on your history and circumstances, care can include a different medication strategy, psychotherapy, or brain-stimulation treatments such as TMS or ECT. Not benefiting from one approach does not mean that no options remain.6
Bring your prescriber a clear account of what you have tried, for how long, what changed, and which side effects got in the way. A useful research article should help you ask better questions—not make you feel that your next chance at relief depends on an unavailable drug.
By Birk Gundersen, RN, BSN.
Words worth knowing
Insomnia
A sleep disorder involving persistent difficulty falling asleep, staying asleep, or getting restorative sleep.
References
- Preskorn et al. (2008) — placebo-controlled proof-of-concept trial of CP-101,606 in treatment-refractory depression
- Stroebel et al. (2016) — structural and functional research on GluN2B-selective allosteric antagonists
- Shelton et al. (2025) — onfasprodil phase 2 trial and background on traxoprodil's QTc-related development halt
- Yurkewicz et al. (2005) — randomized traxoprodil study in severe traumatic brain injury
- Raith et al. (2020) — preclinical EEG and sleep-wake comparisons of traxoprodil and S-ketamine
- National Institute of Mental Health — depression treatment, including care when initial approaches have not helped
